EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine

Donald C Moore, Andrew S Guinigundo

Journal of the Advanced Practitioner in Oncology · 01.04.2023 · 14 (3) · 9-13

DOI: 10.6004/jadpro.2023.14.3.16 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the Advanced Practitioner in Oncology, online erschienen am 01.04.2023. Verfasst von Donald C Moore und 1 weiteren Autor:innen. Beteiligte Einrichtung: From Department of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncology drug development historically has followed a path of sequential phase I, II, and III clinical trials using traditional trial designs, with the goal of achieving regulatory approval. These studies are often conducted with inclusion criteria that limit enrollment to a single tumor type or tumor site of origin, excluding other patients who might also respond. Increased use of precision medicine targeting biomarkers or specific oncogenic mutations has led to novel clinical trial designs that can evaluate these therapies in a less limited fashion. Master protocols such as basket trials, umbrella trials, and platform trials can, for example, evaluate histology-specific therapies targeting a common oncogenic mutation across multiple tumor types or screen for the presence of multiple different biomarkers rather than a single one. In other cases, they can lead to more rapid evaluation of a drug and evaluate targeted therapies in tumor types for which they are not yet currently indicated. As the use of complex biomarker-based master protocols increases, advanced practitioners must understand these novel trial designs, their advantages and disadvantages, and how their use may advance drug development and maximize the clinical benefits of molecular precision therapy.

Autor:innen und Institutionen

  • From Department of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
  • Cincinnati Cancer Advisors, Cincinnati, Ohio.

Zitieren

APA

Moore, D. C., & Guinigundo, A. S. (2023). Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine. Journal of the Advanced Practitioner in Oncology, 14(3), 9-13. https://doi.org/10.6004/jadpro.2023.14.3.16

Vancouver

Moore DC, Guinigundo AS. Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine. Journal of the Advanced Practitioner in Oncology. 2023;14(3):9-13. doi:10.6004/jadpro.2023.14.3.16

BibTeX
@article{Moore2023,
  author = {Moore, Donald C and Guinigundo, Andrew S},
  title = {Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine},
  journal = {Journal of the Advanced Practitioner in Oncology},
  year = {2023},
  volume = {14},
  number = {3},
  pages = {9--13},
  doi = {10.6004/jadpro.2023.14.3.16}
}
Kostenlos starten →